Shengxiang Ren

TL;DR: It is suggested that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive NSCLC, and was associated with more favourable tolerability than standard chemotherapy.

TL;DR: The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.

TL;DR: The present review will focus on the key biological features of IL-2, current applications, limitations, and future directions ofIL-2 in cancer immunotherapy.

TL;DR: This review systematically summarize the recent advances of understanding and identification of tumor-specific neoantigens and its role on current cancer immunotherapies and the ongoing development of strategies based on neoantigen and its future clinical applications.

TL;DR: Single-agent erlotinib was active and well tolerated in NSCLC patients with BM and had significantly longer median PFS versus EGFR wild-type disease.